For many investors, the main point of stock picking is to generate higher returns than the overall market. But in ...

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Over 100 major companies — including MicroStrategy, Coinbase, AMD, Pfizer, and Boeing — are set to report earnings today, July 31. From crypto and AI to healthcare and industrials, here's the full ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most ...

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

Pfizer Inc. (NYSE:PFE) is one of the most undervalued blue chip stocks to buy according to hedge funds. Analyst Tim Anderson from Bank of America Securities maintained a Hold rating on Pfizer Inc.

The American multinational biotech firm developed a form of santonin used to treat intestinal worms, which gained rapid ...

Disclosure: None. This article is originally published at Insider Monkey.

In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025.

On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...

Income-focused investors actively pursuing high yielders should understand what they stand to sacrifice by reaching for a ...